2024-12-01-艾昆纬-印度制药业务季度洞察-2024年第三季度（英）_8页_266kb

Indian Pharmaceutical Business Quarterly Insights – Q3 2024 Summary

Disclaimer

• IQVIA does not provide investment advice or engage in regulated activities under FSMA.
• Forecasts and data are based on third-party sources and are subject to assumptions and uncertainties.
• The report is not a recommendation to buy or sell, and any use or publication requires prior written approval from IQVIA.

Core Performance Overview

• Overall Indian Pharma Value (MAT Sep 2024): ₹60,000 Cr.
• Q3 2024 Growth: 8% PPG (Previous Period Growth).
• MNCs Growth: 7% PPG, slightly lower than Indian companies.
• Top Indian Pharma Companies: Sun, Intas, Torrent, Zydus, Ipca & Glenmark showed double-digit growth.
• Top MNC Pharma Companies: Abbott, AstraZeneca & Merck Specialties reflected good growth.

Therapy Segments Performance

Chronic Therapies

• Overall Growth: 9% PPG.
• Top Growth Areas:
  • Cardiac: 12% PPG.
  • Antineoplastics: 11% PPG.
  • Urology: 13% PPG.
  • Anti-diabetes & Neuro/CNS: 9% PPG.
• Inhalation Preparations: Contributed significantly to Chronic Respiratory growth, despite a negative impact from cough preparations.

Acute Therapies

• Overall Growth: 7% PPG.
• Top Growth Areas:
  • Gastro: 10% PPG.
  • Dermatology: 9% PPG.
  • VMN & Pain: 8% PPG each.
• Single-digit Growth: Anti-infectives, Gynaec, Respiratory (Acute), and Ophthalmology.
• New Launches: Decreased by 9% in 2024 compared to 2023.

Sub-segment Analysis

Anti-Infectives

• Value Growth: 7% PPG.
• Unit Growth: 0.2% PPG.
• Sequential Growth: 25% Value & 27% Unit.
• Key Contributors:
  • Cephalosporins & Ampicillin/Amoxycillin: 8% & 3% PPG.
  • Other Antibiotics: 10% PPG, driven by Piperacillin+Tazobactam (12%) and Teicoplanin (31%).
  • Tetra & Comb: 24% PPG due to Inj & Tigecycline.
  • Carbapenems: 9% PPG, with Meropenem (6%) and Faropenem (15%) as key drivers.

Respiratory (Acute)

• Value Growth: 0.6% PPG.
• Unit Growth: -6% PPG.
• Sequential Growth: 34% Value & 33% Unit.
• Key Trends:
  • Cough Preparations: -46% contribution, with -2% PPG growth.
  • Cold Preparations: -1% PPG, with Cold Prep Liq at -6% PPG.
  • Antihistamines & Nasal Decongestants: 6% & 2% PPG growth respectively.

Pain Management

• Value Growth: 7% PPG.
• Unit Growth: -1% PPG.
• Sequential Growth: 10% Value & 15% Unit.
• Key Contributors:
  • Antirheumatic & Nonsteroidal: 7% PPG.
  • Anti-Pyretics: 8% PPG, with Paracetamol inj showing 26% PPG growth.
  • Muscle Relaxants: 9% PPG.
  • Narcotic Preps, Proteolytic Enzymes, & Antigout Preps: 19%, 23%, and 10% PPG growth respectively.

Gastro-Intestinal

• Value Growth: 10% PPG.
• Unit Growth: 3% PPG.
• Sequential Growth: 2% Value & -9% Unit.
• Key Trends:
  • Antipeptic Ulcerants & Laxatives: 7% & 11% PPG growth.
  • Pantoprazole+Domperidone: 5% PPG.
  • Esomeprazole Plain, Esome+Domp & Panto Inj: 13%, 13%, and 33% PPG growth.

Anti-Diabetes

• Value Growth: 9% PPG.
• Unit Growth: 1% PPG.
• Sequential Growth: 2% Value & -0.3% Unit.
• Key Trends:
  • Oral-Antidiabetes: 8% PPG, driven by SGLT2 combinations (Sita+Metro, Sita+Dapa+Met).
  • Glimipiride+Metformin+Voglibose: ~7% contribution, 5% PPG growth.
  • Vildagliptin Combinations: 4% PPG growth.
  • Insulin Business: 5% PPG growth.

Neuro/CNS

• Value Growth: 9% PPG.
• Unit Growth: -0.2% PPG.
• Sequential Growth: 3% Value & 2% Unit.
• Key Trends:
  • Antidepressants & Antiepileptics: 9% & 10% PPG growth.
  • Gabapentin + Norriptylin: 20% PPG growth.
  • Brivaracetam: Fastest growth at 31% PPG.

Zonal Dynamics

• Total Value (Q3 2024): ₹60,000 Cr.
• QOQ Growth: 8%.
• Top Zones:
  • North & South: Leading contributors with 8% & 9% PPG growth.
  • Delhi, J&K, Telangana, Tamil Nadu: High growth in North & South.
  • East Zone: 6% PPG growth, driven by West Bengal, Kolkata, and Orissa.
  • West Zone: 8% PPG growth, led by Maharashtra and Madhya Pradesh.
  • Top Regions: Uttar Pradesh (11%), West Bengal (11%), Bihar (11%), Telangana (10%), Delhi (11%), and Mumbai (12%) showed strong growth.

Town Class Analysis

• Total Value (Q3 2024): ₹60,000 Cr.
• QOQ Growth: 8%.
• Key Trends:
  • Extra Urban: 6% PPG growth.
  • Metros & Class 1 Towns: Both grew at 9% PPG.
  • Top Metro Growth: Delhi (13%), Hyderabad (12%), Chennai (15%), Pune (17%), Lucknow (14%), Agra (13%), and Nagpur (12%).

Conclusion

The Indian pharmaceutical sector showed strong performance in Q3 2024, with an overall value growth of 8% PPG. Chronic therapies outperformed acute ones, driven by growth in Cardiac, Antineoplastics, and Urology. While some segments like Anti-infectives and Respiratory (Acute) showed single-digit growth, others like Pain and Gastro-Intestinal demonstrated resilience. Key regions and towns, especially metros, continued to be major contributors to growth, highlighting the importance of urban markets in the sector's expansion.